Reviewing Ultragenyx Pharmaceutical Inc. (RARE)’s and Ardelyx Inc. (NASDAQ:ARDX)’s results

We will be comparing the differences between Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Ardelyx Inc. (NASDAQ:ARDX) as far as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ultragenyx Pharmaceutical Inc. 37.65M 73.58 191.52M -2.43 0.00
Ardelyx Inc. 44.52M 3.63 53.32M -0.96 0.00

In table 1 we can see Ultragenyx Pharmaceutical Inc. and Ardelyx Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 has Ultragenyx Pharmaceutical Inc. and Ardelyx Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Ultragenyx Pharmaceutical Inc. -508.69% -31% -26.6%
Ardelyx Inc. -119.77% -37.2% -29%

Risk & Volatility

A 2.34 beta means Ultragenyx Pharmaceutical Inc.’s volatility is 134.00% more than Standard and Poor’s 500’s volatility. Ardelyx Inc.’s 1.38 beta is the reason why it is 38.00% more volatile than Standard and Poor’s 500.

Liquidity

Ultragenyx Pharmaceutical Inc.’s Current Ratio is 8.5 while its Quick Ratio is 8.4. On the competitive side is, Ardelyx Inc. which has a 12.8 Current Ratio and a 12.8 Quick Ratio. Ardelyx Inc. is better positioned to pay off short and long-term obligations compared to Ultragenyx Pharmaceutical Inc.

Analyst Ratings

In next table is given Ultragenyx Pharmaceutical Inc. and Ardelyx Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ultragenyx Pharmaceutical Inc. 0 4 3 2.43
Ardelyx Inc. 0 0 1 3.00

Ultragenyx Pharmaceutical Inc. has an average price target of $71.14, and a 29.89% upside potential. Competitively the consensus price target of Ardelyx Inc. is $7, which is potential 169.23% upside. The results provided earlier shows that Ardelyx Inc. appears more favorable than Ultragenyx Pharmaceutical Inc., based on analyst opinion.

Institutional & Insider Ownership

The shares of both Ultragenyx Pharmaceutical Inc. and Ardelyx Inc. are owned by institutional investors at 0% and 85.2% respectively. Insiders held roughly 0.5% of Ultragenyx Pharmaceutical Inc.’s shares. On the other hand, insiders held about 1.4% of Ardelyx Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ultragenyx Pharmaceutical Inc. -11.27% -11.17% -43.64% -40.33% 3.14% 2.67%
Ardelyx Inc. -10.29% -28.86% -35.79% -39.75% -58.99% -63.03%

For the past year Ultragenyx Pharmaceutical Inc. had bullish trend while Ardelyx Inc. had bearish trend.

Summary

Ardelyx Inc. beats Ultragenyx Pharmaceutical Inc. on 8 of the 12 factors.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude ChildrenÂ’s Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.